[1] |
Baumann L, Cina M, Egli⁃Gany D, et al. Prevalence of Mycoplasma genitalium in different population groups: systematic review and meta⁃analysis[J]. Sex Transm Infect, 2018. [published online ahead of print Feb 9, 2018]. doi: 10.1136/sextrans⁃2017⁃053384.<br />
|
[2] |
Jensen JS, Cusini M, Gomberg M, et al. 2016 European guideline on Mycoplasma genitalium infections[J]. J Eur Acad Dermatol Venereol, 2016,30(10):1650⁃1656. doi: 10.1111/ jdv. 13849.<br />
|
[3] |
Getman D, Jiang A, O′Donnell M, et al. Mycoplasma genitalium prevalence, coinfection, and macrolide antibiotic resistance frequency in a multicenter clinical study cohort in the United States[J]. J Clin Microbiol, 2016,54(9):2278⁃2283. doi: 10.1128/JCM.01053⁃16.<br />
|
[4] |
Gratrix J, Plitt S, Turnbull L, et al. Prevalence and antibiotic resistance of Mycoplasma genitalium among STI clinic attendees in Western Canada: a cross⁃sectional analysis[J]. BMJ Open, 2017,7(7):e016300. doi: 10.1136/bmjopen⁃2017⁃016300.<br />
|
[5] |
Lockhart A, Psioda M, Ting J, et al. Prospective evaluation of cervico⁃vaginal self and cervical physician⁃collection for the detection of Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium infections[J]. Sex Transm Dis, 2018. https://insights.ovid.com/pubmed?pmid=29465667. [published online ahead of print Jan 2, 2018]. doi: 10.1097/OLQ.0000000000000778.<br />
|
[6] |
Zheng BJ, Yin YP, Han Y, et al. The prevalence of urethral and rectal Mycoplasma genitalium among men who have sex with men in China, a cross⁃sectional study[J]. BMC Public Health, 2014,14:195. doi: 10.1186/1471⁃2458⁃14⁃195.<br />
|
[7] |
Chen LS, Wu JR, Wang B, et al. Epidemiology of Mycoplasma acquisition in male HIV⁃1 infected patients: a multistage cross⁃sectional survey in Jiangsu, China[J]. Epidemiol Infect, 2015,143(15):3327⁃3334. doi: 10.1017/S0950268815000461.<br />
|
[8] |
Zheng BJ, Yin YP, Xiang Z, et al. An epidemiological study of Mycoplasma genitalium infections among males attending a sexually transmitted disease clinic in Guangxi, China[J]. Jpn J Infect Dis, 2014,67(1):17⁃21.<br />
|
[9] |
Moi H, Reinton N, Moghaddam A. Mycoplasma genitalium is associated with symptomatic and asymptomatic non⁃gonococcal urethritis in men[J]. Sex Transm Infect, 2009,85(1):15⁃18. doi: 10.1136/sti.2008.032730.<br />
|
[10] |
Gaydos CA. Mycoplasma genitalium: accurate diagnosis is necessary for adequate treatment[J]. J Infect Dis, 2017,216(suppl 2):S406⁃406S411. doi: 10.1093/infdis/jix104.<br />
|
[11] |
Smieszek T, White PJ. Apparently⁃Different Clearance Rates from cohort studies of Mycoplasma genitalium are consistent after accounting for incidence of infection, recurrent infection, and study design[J]. PLoS One, 2016,11(2):e0149087. doi: 10.1371/journal.pone.0149087.<br />
|
[12] |
Bradshaw CS, Jensen JS, Waites KB. New horizons in Mycoplasma genitalium treatment[J]. J Infect Dis, 2017,216(suppl 2):S412⁃412S419. doi: 10.1093/infdis/jix132.<br />
|
[13] |
Bradshaw CS, Jensen JS, Tabrizi SN, et al. Azithromycin failure in Mycoplasma genitalium urethritis[J]. Emerg Infect Dis, 2006,12(7):1149⁃1152. doi: 10.3201/eid1207.051558.<br />
|
[14] |
Lau A, Bradshaw CS, Lewis D, et al . The efficacy of azithromycin for the treatment of genital Mycoplasma genitalium: a systematic review and meta⁃ analysis [J]. Clin Infect Dis, 2015,61(9):1389⁃1399. doi: 10.1093/cid/civ644.<br />
|
[15] |
Gesink D, Racey CS, Seah C, et al. Mycoplasma genitalium in Toronto, Ont: estimates of prevalence and macrolide resistance[J]. Can Fam Physician, 2016,62(2):e96⁃101.<br />
|
[16] |
Pitt R, Fifer H, Woodford N, et al. Detection of markers predictive of macrolide and fluoroquinolone resistance in Mycoplasma genitalium from patients attending sexual health services in England[J]. Sex Transm Infect, 2018,94(1):9⁃13. doi: 10.1136/sextrans⁃2017⁃053164.<br />
|
[17] |
Tabrizi SN, Su J, Bradshaw CS, et al. Prospective evaluation of resistance plus MG, a new multiplex quantitative PCR assay for detection of Mycoplasma genitalium and macrolide resistance[J]. J Clin Microbiol, 2017,55(6):1915⁃1919. doi: 10.1128/JCM. 02312⁃16.<br />
|
[18] |
Basu I, Roberts SA, Bower JE, et al. High macrolide resistance in Mycoplasma genitalium strains causing infection in Auckland, New Zealand[J]. J Clin Microbiol, 2017,55(7):2280⁃2282. doi: 10.1128/JCM.00370⁃17.<br />
|
[19] |
Li Y, Le WJ, Li S, et al. Meta⁃analysis of the efficacy of moxi⁃floxacin in treating Mycoplasma genitalium infection[J]. Int J STD AIDS, 2017,28(11):1106⁃1114. doi: 10.1177/0956462416688562.<br />
|
[20] |
Soni S, Parkhouse A, Dean G. Macrolide and quinolone⁃resistant Mycoplasma genitalium in a man with persistent urethritis: the tip of the British iceberg?[J]. Sex Transm Infect, 2017,93(8):556⁃557. doi: 10.1136/sextrans⁃2016⁃053077.<br />
|
[21] |
Couldwell DL, Tagg KA, Jeoffreys NJ, et al. Failure of moxi⁃floxacin treatment in Mycoplasma genitalium infections due to macrolide and fluoroquinolone resistance[J]. Int J STD AIDS, 2013,24(10):822⁃828. doi: 10.1177/0956462413502008.<br />
|
[22] |
Anderson T, Coughlan E, Werno A. Mycoplasma genitalium macrolide and fluoroquinolone resistance detection and clinical implications in a selected cohort in New Zealand[J]. J Clin Microbiol, 2017,55(11):3242⁃3248. doi: 10.1128/JCM.01087⁃17.<br />
|
[23] |
Barberá MJ, Fernández⁃Huerta M, Jensen JS, et al. Mycoplasma genitalium macrolide and fluoroquinolone resistance: prevalence and risk factors among a 2013⁃2014 cohort of patients in Barcelona, Spain[J]. Sex Transm Dis, 2017,44(8):457⁃462. doi: 10.1097/OLQ.0000000000000631.<br />
|
[24] |
Deguchi T, Yasuda M, Horie K, et al. Drug resistance⁃associated mutations in Mycoplasma genitalium in female sex workers, Japan[J]. Emerg Infect Dis, 2015,21(6):1062⁃1064. doi: 10.3201/eid2106.142013.<br />
|
[25] |
Murray GL, Bradshaw CS, Bissessor M, et al. Increasing macrolide and fluoroquinolone resistance in Mycoplasma genitalium[J]. Emerg Infect Dis, 2017,23(5):809⁃812. doi: 10.3201/eid2305. 161745.<br />
|
[26] |
Shimada Y, Deguchi T, Nakane K, et al. Emergence of clinical strains of Mycoplasma genitalium harbouring alterations in ParC associated with fluoroquinolone resistance[J]. Int J Antimicrob Agents, 2010,36(3):255⁃258. doi: 10.1016/j.ijantimicag.2010. 05.011.<br />
|
[27] |
TRH R, Jensen JS, Fairley CK, et al. Use of pristinamycin for macrolide⁃resistant Mycoplasma genitalium infection[J]. Emerg Infect Dis, 2018,24(2):328⁃335. doi: 10.3201/eid2402.170902.<br />
|
[28] |
Falk L, Jensen JS. Successful outcome of macrolide⁃resistant Mycoplasma genitalium urethritis after spectinomycin treatment: a case report[J]. J Antimicrob Chemother, 2017,72(2):624⁃625. doi: 10.1093/jac/dkw405.<br />
|
[29] |
Deguchi T, Ito S, Yasuda M, et al. Emergence of Mycoplasma genitalium with clinically significant fluoroquinolone resistance conferred by amino acid changes both in GyrA and ParC in Japan[J]. J Infect Chemother, 2017,23(9):648⁃650. doi: 10.1016/j.jiac.2017.03.008.<br />
|